MedTrace Logo

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

NCT01199757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 540

Last updated 2017-08-14

No results posted yet for this study

Summary

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Fluticasone furoate

cohort of patients receiving fluticasone furate

DRUG

mometasone furoate

cohort receiving mometasone furoate

DRUG

fluticasone propionate

cohort of patients on fluticasone propionate

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-10
Primary Completion
2009-08-01
Completion
2009-08-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01199757 on ClinicalTrials.gov